MedLea

MedLea is an Italian medical-technology company that develops image-analysis and computational modelling software for medical radiology and lung care. Its core offering is a patient-specific "virtual lung": a digital model of lung structure and function reconstructed from multimodal clinical and radiological data. The company positions this model as evidence-based insight for thoracic surgery and critical-care research, rather than as a diagnostic device for routine clinical use. The platform is organised around several use cases. Functional lung reconstruction rebuilds organs with patient-specific pathophysiology from multimodal clinical and radiological data. Adaptive ventilation supports patient-specific ventilation strategies in the intensive care unit. Predictive analysis produces risk maps and AI-derived biomarkers for surgery, ICU and prognostic research. Pharmacological simulations allow in-silico evaluation of drug response on lung structure and function. Pre-operative evaluation lets clinicians plan thoracic interventions on a patient-specific digital twin before entering the operating room. MedLea frames the clinical problem in economic and safety terms. It argues that inaccurate management of lung function drives complications and unreimbursed healthcare costs, that ventilation mismatched to the patient can injure the lung, and that patients return to hospital after discharge. Its proposed answer is an agentic workflow in which multimodal clinical and radiological data are processed automatically, cardiorespiratory organs are reconstructed with patient-specific pathophysiology, and morphofunctional information is derived for downstream analysis. The company is based in Italy and operates a website at medlea-tech.com. Public information about its founding, ownership, leadership and funding is limited; the available evidence describes it as an Italian company providing image analysis for medical radiology and as the developer of the virtual-lung platform. Its focus on in-silico and research-oriented applications places it in the emerging field of computational medicine and digital twins for healthcare.

MedLea is an Italian medical-technology company whose public profile centres on image analysis for medical radiology and on a patient-specific virtual-lung platform for surgery and critical care. The available evidence does not record a founding date, founding team, funding history or corporate ownership structure, so its early history cannot be reconstructed in detail here. What is documented is the product concept and the clinical problem it addresses. MedLea states that inaccurate management of lung function drives complications and unreimbursed healthcare costs, that ventilation mismatched to the patient can injure the lung, and that patients return to hospital after discharge. Its response is a virtual lung that models lung function from clinical and radiological data, described as evidence-based insight for surgery and critical-care research. The platform is built around an agentic workflow. Multimodal clinical and radiological data are processed automatically; cardiorespiratory organs are reconstructed with patient-specific pathophysiology; and morphofunctional information is derived for analysis. From this base, MedLea lists five use cases: functional lung reconstruction, adaptive ventilation for the ICU, predictive analysis with risk maps and AI-derived biomarkers, pharmacological simulations for in-silico drug-response evaluation, and pre-operative evaluation that lets clinicians plan thoracic interventions on a patient-specific digital twin before entering the operating room. MedLea operates from Italy and maintains its web presence at medlea-tech.com. Beyond this, the public record is thin: no leadership names, no disclosed investors, no regulatory clearances and no commercial deployments are evidenced in the supplied material. The company should therefore be understood as an early-stage or emerging computational-medicine venture whose identity rests on its virtual-lung technology and its research-oriented positioning rather than on a long corporate history.

Evidence-based, patient-specific computational modelling of lung function for thoracic surgery and critical-care research, addressing complications and unreimbursed costs from inaccurate lung-function management.

• Virtual Lung

  A patient-specific virtual lung that models lung function from clinical and radiological data, providing evidence-based insight for surgery and critical-care research.

• Functional lung reconstruction

  Reconstructs organs with patient-specific pathophysiology from multimodal clinical and radiological data.

• Adaptive ventilation

  Patient-specific ventilation strategy support for the ICU.

• Predictive analysis

  Risk maps and AI-derived biomarkers for surgery, ICU and prognostic research.

• Pharmacological simulations

  In-silico evaluation of drug response on lung structure and function.

• Pre-operative evaluation

  Plan thoracic interventions on a patient-specific digital twin before entering the OR.

1. 1Virtual Lung for surgery and critical care · Medleamedlea-tech.com
2. 2MedLea — Wikidatawikidata.org